A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
PHASE3CompletedINTERVENTIONAL
Enrollment
463
Participants
Timeline
Start Date
May 31, 2012
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL
Adalimumab
Adalimumab pre-filled syringe, administered by subcutaneous injection
All Listed Sponsors
lead
AbbVie (prior sponsor, Abbott)
INDUSTRY
NCT01550965 - A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting | Biotech Hunter | Biotech Hunter